Myelofibrosis (MF) is a serious subtype of myeloproliferative neoplasm (MPN) with a typically poor prognosis, highlighting the need for better understanding of its causes.
Key mutations in three genes (JAK2, CALR, and MPL) frequently appear in MPN and can trigger the disease in animal models, indicating their significance in MF development.
Research using these animal models has provided insights into MF's progression from earlier stages of MPN, like essential thrombocythemia and polycythemia vera, and has opened doors to potential new therapies.